Dendritic cell-based therapies have been exploited as immunotherapeutic approaches for cancer treatment. Here the authors report a platform integrating antigen-capturing nanoparticles and type 1 conventional dendritic cells for in situ cancer immunization, promoting anti-tumor immunity in preclinical models.
- Chih-Jia Chao
- Endong Zhang
- Zongmin Zhao
